Clinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol - Summary - MDSpire

Clinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol

  • By

  • Jinyi Fu

  • Yifei Qi

  • Jingyi Zhan

  • Linjing Su

  • Yucong Gao

  • Qingbing Zhou

  • Ying Zhang

  • June 3, 2026

  • 0 min

Share

Objective:

To evaluate the clinical efficacy and safety of Yiqi-Yangyin-Huoxue (YQYYHX) granules in patients with Type 2 diabetes mellitus (T2DM) and early vascular aging (EVA), and to explore its potential mechanisms.

Key Findings:
  • YQYYHX granules contain compounds such as daidzin, salvianolic acid L, and oleamide.
  • The trial is expected to provide evidence on the efficacy and safety of YQYYHX in treating T2DM and EVA.
Interpretation:

Remove unsupported conclusions.

Limitations:
  • Single-center study may limit generalizability.
  • Results are pending as recruitment is ongoing.
Conclusion:

Revise to avoid implications about potential benefits.

Original Source(s)

Clinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabetes mellitus and early vascular aging: a randomized, double-blind, placebo-controlled trial protocol

  • by Jinyi Fu, Yifei Qi, Jingyi Zhan, Linjing Su, Yucong Gao, Qingbing Zhou, Ying Zhang

  • June 3, 2026

Related Content

AHA Updates Diet Guidance, Highlights Plant Shift

Revised American Heart Association statement urges a shift toward plant-based protein and flags ongoing uncertainty in fat and alcohol recommendations.

AACE 2026: AI moves from hype to reality in diabetes care

"Right now, AI is more of a copilot, but the long-term vision is something much closer to autopilot."

AI Screening for Diabetic Retinopathy